Business Model

The AFAR business model focuses on R&D, aggressive patenting and completion of license deals with large Pharma companies interested in selling our innovative and scientifically proven products. AFAR is  HSA (Singapore), CE (Europe), ANVISA (Brazil) and TGA (Australia) regulated. We are awaiting clearance from FDA following submission final testing requirements.

100-whitebg